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There has been a high local recurrence rate in rectal cancer. Besides improvements in surgical techniques, both neoadjuvant short-
course radiotherapy and long-course chemoradiation improve oncological results. Approximately 40–60% of rectal cancer patients
treated with neoadjuvant chemoradiation achieve some degree of pathologic response. However, there is no effective method of
predicting which patients will respond to neoadjuvant treatment. Recent studies have evaluated the potential of genetic biomarkers
to predict outcome in locally advanced rectal adenocarcinoma treated with neoadjuvant chemoradiation. The articles produced
by the PubMed search were reviewed for those specifically addressing a genetic profile’s ability to predict response to neoadjuvant
treatment in rectal cancer. Although tissue gene microarray profiling has led to promising data in cancer, to date, none of the
identified signatures or molecular markers in locally advanced rectal cancer has been successfully validated as a diagnostic or
prognostic tool applicable to routine clinical practice.
1. Introduction
Colorectal cancer is the third most frequent cancer and
the second most frequent cause of cancer related death,
both in Europe [1]. The proportion of rectal cancer cases
is variable depending on the cancer registry and classi-
fication of rectosigmoid tumours, ranging from 27% to
58% [2]. The ideal treatment recommendations for rectal
cancer are under permanent appraisal; nevertheless, studies
have demonstrated that, for locally advanced rectal can-
cer (LARC) (stage T3, stage T4, or node-positive disease),
preoperative (neoadjuvant) chemoradiation (CRT) signif-
icantly improves local control and reduces toxicity pro-
files compared with postoperative CRT but with similar
survival rates [3, 4]. Furthermore, the ability to achieve
pathologic downstaging, or a complete pathologic response
(pCR), after neoadjuvant CRT is correlated with improved
survival, decreased local recurrence, and a higher rate of
sphincter-preserving surgeries [5]. Approximately 40–60%
of LARC patients treated with neoadjuvant CRT achieve
some degree of pathologic response. However, there is no
effective method of predicting which patients will respond to
neoadjuvant CRT [6]. Prospective identification of patients
who have a higher likelihood of responding to preoperative
CRT could be important in deceasing treatment morbid-
ity and improving survival and local control in LARC.
In addition, patients who are unlikely to respond could
be offered alternative approaches to therapy. Recent stud-
ies have evaluated the potential of genetic biomarkers to
predict outcome in LARC treated with neoadjuvant CRT
[7, 8]. The goal of this review is to examine the current
literature for the most commonly researched biomarkers
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2. Material and Methods
An exhaustive search of PubMed was performed on March,
2014, with combinations of the following terms: “rectal can-
cer,” “response,” “prediction,” “microarray,” “gene expres-
sion,” “mi-RNA,” and “ln- RNA.” The articles produced
by the PubMed search were reviewed for those specifically
addressing a genetic profile’s ability to predict response
to neoadjuvant CRT in LARC (genes, microRNA, or long
noncoding RNA). Articles analysing response prediction to
CRT in colorectal cancer cell lines were excluded. Sixteen
studies evaluating genetic profiles predicting outcome of
neoadjuvant CRT in rectal cancer were found. Ten of them
identified an over- or downregulated gene signature, 5 found
microRNA (miRNA) signature. Only one screened long non-
coding RNA (lncRNA) was associated with radiosensitivity
but was made in colorectal cancer cell lines and was written
in Chinese and therefore was excluded.
3. Results
3.1. Prediction of Response Based on DNA Microarrays in
Tumor Tissue (prior to Neoadjuvant Treatment) (Table 1).
The first study on the application of a genetic signature to
predict response to neoadjuvant treatment in rectal cancer
appeared in 2005 [9]. It included 30 patients from a data
base pertaining to the German Group for the Study of
Rectal Cancer [22] who received preoperative chemoradia-
tion therapy (50.4Gy of radiation, applied in 28 fractions
and continuous infusion of 5FU). They underwent surgery
6 weeks following completion of the neoadjuvant therapy.
Response to treatment was measured by the following: tumor
shrinkage (when compared with a preoperative ultrasound
scan, uT) and the stages of tumor remission under Dworak’s
regression grades (3-4 considered to be responders) [23].
Based on downsizing or tumor shrinkage they identified 54
genes expressed differently between responders versus non-
responders in tumor samples extracted prior to neoadjuvant
therapy. By using these genes they attained 83% precision
in the prediction, both for responders and nonresponders,
thus proving that the study of genetic expression through
microarrays was useful in predicting a reduction in tumor
size (measured by the decrease of ypT in relation to uT) in
response to preoperative CRT therapy. These 54 genes are
involved in many biological functions, including repairing
damage to cellular DNA (SMC1), organizing microtubules
(CLMN and CDC42BPA), and cellular signaling (FLNB).
The following year a Japanese group with a similar
objective, published a microarray analysis of DNA [10]
that analyzed a total of 52 patients. Neoadjuvant therapy
consisted of preoperative radiotherapy (50.4Gy) without any
chemotherapy, followed by a four-week rest period and then
surgery.The evaluation of response was determined based on
an anatomical pathological analysis of the surgical sample,
employing a Japanese semiquantitative scale that identified
stages 2-3 as responders and stages 0-1 as nonresponders.
A group of 33 differentially expressed genes was established
among responders and nonresponders: 20 were overex-
pressed genes related to apoptosis such as lumican (LUM),
thrombospondin 2 (THBS2), and galectin-1 (LGALS1), while
13 were repressed in the responder-group, such as cyclophilin
40 (CYP40) and glutathione peroxidase 2 (GPX2). A protein
structure prediction was then done on 33 genes from 17
patients included in the validation group, which found
82.4% exactness for determining class, 50% sensibility, 100%
specificity, a positive predictive value of 100%, and a negative
predictive value of 76.6%.
Kim and colleagues conducted a study in 2007 using
samples from 46 patients (31 for the initial trial group and
15 for the validation) [11]. Neoadjuvant treatment included
radiotherapy (50.4Gy in 28 fractions) and chemotherapy
(5FU + leucovorin, capecitabine or capecitabine + irinote-
can). Patients underwent surgery 6 weeks after completion
of treatment; tumor response was classified according to
Dworak’s tumor regression grade system. They identified
a group of 95 genes and applied the leave-one-out-cross-
validation (LOOCV) method to predict response and found
that this group of genes enabled tumor response to be pre-
dicted with 84% precision, 64% sensibility, 95% specificity, an
88% positive predictive value and an 87% negative predictive
value. The validation group reached 87% precision, 100%
sensibility, and 82% specificity. Two of the 95 genes stood out:
thymidylate synthase (TYMS, involved in DNA synthesis),
which was highly expressed in responding tumors, and
RAD23B (involved in nucleotide excision repair), which was
elevated in nonresponders and has previously been associated
with patients resistant to treatmentwith 5FU.These two genes
could be used to evaluate response to treatment with 5FU.
Rimkus et al. [12] also studied the tumor biopsies of
patients in stage T3. The therapeutic approach used involved
radiation (45Gy) and continuous infusion of 5FU. Surgery
was done following a 4–6-week rest period. The anatomical
pathological response was classified according to Becker’s
regression grade (responders in stage 1 and nonresponders
in stages 2-3). They found 42 statistically significant genes
that were expressed differently among responders and non-
responders. Five of them (FREM1, M-RIP, SDHC, TDE1, and
USP42) had a reduced expression in the group of responders,
while the rest of the genes were overexpressed and involved
in apoptosis (CASP1), transport (SLC35E1), cellular signaling
(STAT2 and ETS2), and cellular cycle (CCNK). Sensibility
was 71%, specificity was 86%, positive predictive value was
71%, and negative predictive value was 86%.
More recently, a group formedbyNishioka and colleagues
[13] included 20 patients (17 in a trial group and 3 in the
validation unit) who received radiotherapy (40Gy in frac-
tions of 2Gy), associated with S1, an oral chemotherapeutic
agent whose action is similar to capecitabine, not currently
authorized for use in Europe.They used a response scale from
the Japanese Society for Cancer of the Colon and Rectumthat
classified patients in groups 0-1 as nonresponders and those
in groups 2-3 as responders. A microarray of 132 genes
related to a response to 5FU was used in addition to other
chemotherapeutics. Researchers identified 17 genes expressed
differently among the two patient subgroups (responders ver-
sus nonresponders). Of them, five were metalloproteinases
(MMP1, MMP7, MMP9, MMP14, and MMP16). In addition,
they conducted an immunological and histological chemical
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study to evaluate expression of the MMP7 protein, whose
gene was the one most overexpressed in normal tissue.
Among responders, four patients overexpressedMMP7 (4/10,
40%), while none in the group of nonresponders expressed
that protein. These 17 genes were used to classify samples
from the validation group and were correct in three cases. It
is worth emphasizing that in the nonresponder case none of
the genes were overexpressed.
Our group [7] identified a 4-gene profile (C-MYC,
GNG4, POLA, and RRM1) associated with response to
preoperative chemoradiotherapy in rectal cancer patients.
The microarrays study included a total of 35 patients with
LARC with additional 8 patients in the validation group.
Tumor samples were prospectively obtained before treatment
(total dose of 50.4Gy of radiation in 28 fractions of 1.8 Gy
associated with capecitabine alone or capecitabine combined
with oxaliplatin). Tumor response was assessed in surgical
specimens by pathological examination based on Mandard’s
tumor regression grading (TRG) system [24]: TRG 1 and
TRG 2 scores were considered responders, whereas TRG 3,
TRG 4, and TRG 5 scores were classified as nonresponders.
To validate microarray experimental data, expression levels
of 20 genes in rectal tumor patients were obtained by real-
time quantitative reverse transcription PCR. 257 genes were
overexpressed in responders, but only 4 were confirmed with
PCR. High expression levels of the 4 genes (Gng4, c-Myc,
Pola1, and Rrm1) were a significant prognostic factor for
response to treatment in LARC patients. Using this gene
set, a new model for predicting the response to CRT in
rectal cancer was established with a sensitivity of 60% and
100% specificity. For each of the genes Gng4, c-Myc, Pola1,
and Rrm1, receiver operating characteristic (ROC) curves
were computed. The one with the higher AUC was c-Myc,
with a sensitivity of 70% and a specificity of 100% at a cut-
off point set at 64.45. Functional analysis showed that the
encoding proteins were associated with several canonical
pathways (pyrimidine and purine metabolism, colorectal
cancer metastasis signalling). The most significant network
consisting of 49 genes contained 24 focus genes directly or
indirectly connected to a c-Myc network.
Granttet published a study in 2014 using high-throughput
nucleotidemicroarrays to develop a genetic profile associated
with CRT-resistant rectal cancer. Thirty-three patients were
incorporated in the study [15]. Patients who met clinical
criteria for neoadjuvant CRT underwent biopsy of the
tumour. The treatment regimen included 50.4Gy radiation
in 30 fractions with 5-fluorouracil. Patients underwent cura-
tive surgery approximately 8–10 weeks after completion of
CRT. Posttreatment responses were assessed according to
the American Joint Committee on Cancer (AJCC) criteria
considering patients with AJCC 0–2 as responders and those
with AJCC 3 as nonresponders. They identified a unique
gene expression profile composed of 812 genes associated
with rectal cancer that had a poor response to CRT. This
profile enabled the classification of nonresponders with
100% accuracy in a small validation group (sensitivity and
specificity of 100% for predicting nonresponders). Using the
183-gene profile, specificity remained 100%, while sensitivity
decreased to 33.3%. The top 10 upregulated genes included
APOA2, AHSG, DBH, APOA1, APOB, APOC3, LMX1A,
SOAT2, SLC7A9, and TF. The top 10 downregulated genes
included LOC729399, SERINC5, SCNN1B, ZC3H6, SLC4A4,
DTWD2, MS4A12, BEX5, MMRN1, and CLCA4. Functional
analysis of differentially expressed genes with IPA soft-
ware (Ingenuity Pathways Analysis) revealed “DNA repair
by homologous recombination” as a statistically significant
canonical pathway in this study with RAD50 as the most sig-
nificant differentially expressed gene in this pathway. RAD50
is a member of the MRE11-RAD50-NBS1 (MRN) complex
that detects double-strandedDNA breaks and regulates DNA
damage repair primarily through homologous recombina-
tion. A number of apolipoprotein genes were upregulated
in nonresponders (APOA2, APOA1, APOB, and APOC3).
AHSG is a serum glycoprotein involved in endocytosis, brain
development, and the formation of bone tissue previously
associated with resistance to neoadjuvant chemotherapy in
patients with advanced breast cancer. LMX1A is known to be
involved in insulin gene transcription and the embryogenesis
of dopamine-producing neurons. In cancer, LMX1A has been
shown to be a poor prognostic indicator in ovarian and
pancreatic tumors but LMX1A was also recently shown to
inhibit cell proliferation, migration, invasion, and colony
formation in vitro.
Recently, Watanabe conducted a new study to estab-
lish a prediction model for response to chemoradiother-
apy in rectal cancer based on gene expression by RT-PCR
analysis as it allows accurate and reproducible quantifica-
tion of genes [16]. Biopsy specimens were collected before
preoperative treatment (50.4Gy in 28 fractions during 6
weeks concomitantly with tegafur-uracil and leucovorin).
Standardized curative resection was performed 6 weeks
after the completion of chemoradiotherapy. Response to
chemoradiotherapy was determined by histopathological
examination of surgically resected specimens based on a
semiquantitative classification systemdefined by the Japanese
Society for Cancer of the Colon and Rectum. Tumors were
classified as “nonresponders” when assigned to grade 0
or grade 1 and “responders” when assigned to regression
grade 2 or grade 3. First, gene expression profiles were
determined by DNA microarray analysis on 46 training
samples. They identified 24 probes that were differentially
expressed between responders and nonresponders. Twenty
genes showed higher and four genes showed lower expression
in nonresponders compared with responders. Microarray
expression levels were validated by quantitative RT-PCR
of 18 genes (that were represented among the 24 probes)
in the 46 training samples, showing significant differences
in the expression levels of 16 of the 18 genes (20 probes)
between responders and nonresponders. Based on the 16
genes and their combination, the predictive accuracies of
the 2500 different sets of predictor genes were calculated.
The highest accuracy rate (89.1%) was obtained with a 4-
gene set including LRRIQ3, FRMD3, SAMD5, and TMC7.
This 4-gene signature was validated in an independent
cohort of 16 patients. Predictive accuracy rate was 81.3%
and sensitivity, specificity, positive predictive value, and
negative predictive value were 100%, 62.5%, 72.7%, and 100%,
respectively.
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3.2. Prediction of Response Based on Microarrays of Gene
Expression in Peripheral Blood. Peripheral blood mononu-
clear cells have emerged recently as pathology markers of
cancer and other diseases, making their use as therapy
predictors possible. Furthermore, the importance of the
immune response in radiosensitivity of solid organs led
Palma et al. [8] to hypothesize that microarray gene expres-
sion profiling of peripheral blood mononuclear cells could
identify patients with response to CRT in LARC. Thirty-
five 35 patients with locally advanced rectal cancer were
recruited initially to perform the study. Peripheral blood
samples were obtained before neoadjuvant treatment. RNA
was extracted and purified to obtain cDNA and cRNA
for hybridization of microarrays included in Human WG
CodeLink bioarrays. Quantitative real-time PCR was used to
validate microarray experiment data. Results were correlated
with pathological response, according to Mandard’s criteria
and final UICC Stage (patients with tumor regression grades
1-2 and downstaging being defined as responders and patients
with grades 3–5 and no downstaging as nonresponders).
The authors performed a multiple 𝑡-test using Significance
Analysis of Microarrays to find those genes differing sig-
nificantly in expression between responders (𝑛 = 11) and
nonresponders (𝑛 = 16) to CRT. The differently expressed
genes were BC 035656.1, CIR, PRDM2, CAPG, FALZ, HLA-
DPB2, NUPL2, and ZFP36. The measurement of FALZ (𝑃 =
0.029) gene expression level determined by qRT-PCR showed
statistically significant differences between the two groups.
Theypostulated the idea that gene expression profiling reveals
novel genes in peripheral blood samples of mononuclear
cells that could predict responders and nonresponders to
CRT in patients with LARC. The authors hypothesized the
importance of mononuclear cells’ mediated response in the
neoadjuvant treatment of rectal cancer.
3.3. Prediction of Response Using Microarrays of MicroRNA
(Table 2). MicroRNAs (miRNAs), discovered in 1993, repre-
sent a relatively new field in the rapidly developing world of
genetics and the regulation of genetic expression. AmiRNA is
a small sequence of single-stranded RNA (normally between
18 and 25 nucleotides) that do not code proteins but do
act as posttranscriptional regulators of genetic expression.
They act by binding to complementary strands of messenger
RNA, usually inhibiting expression and silencing the gene.
Their function can be very similar to the function of onco-
genes as well as tumor-suppressing genes [25]. The aberrant
expression of miRNA is involved in numerous pathologies
and some alterations in its regulation have been associated
with colorectal cancer. Furthermore, it has been determined
that CRT in LARC can induce alterations in the expression
of miRNA in normal tissue samples and these have been
associated with positive response to treatment [26].
Changes in miRNA expression can be induced as a
consequence of various external stimuli such as hypoxia
and gemcitabine. Svoboda and colleagues studied changes of
selected microRNAs in rectal cancer biopsies from patients
treatedwith chemoradiotherapy (50.4Gy in 1.8 fractions con-
comitantly with capecitabine) and correlation with response
[17]. Microexcision biopsies were taken from the same rectal
cancers before therapy and subsequently two weeks after
starting preoperative chemoradiotherapy treatment. Radical
surgery was performed within the 6th week after completion
of neoadjuvant treatment. Tumor response to therapy was
assessed microscopically by the Dworak tumor regression
grade system. Following a pilot study of normal mucosa
biopsies researchers found that microRNAs mi-R125b and
mi-R137 showed significant induction and exhibited the same
expression trends in most samples two weeks after starting
therapy, so they were chosen for further analysis in the
total sample set. Real-time PCR was performed and relative
expressions of microRNA were determined. Patients with
early tumors have lower induction than patients with higher
stage cancers. MiR125b is downregulated in several cancers
and thought to act as a tumor suppressor. In this study,
tumors with the highest upregulation of mi-R125b level two
weeks after starting therapy showed no downstaging and
less regression (poor response). Mi-R137 was significantly
upregulated only in the most advanced T-stage. Researchers
concluded that higher induced levels of mi-R125b and mi-
R137 were associated with a worse response to the therapy.
In 2012 Della Vittoria Scarpati and colleagues published
an article based on this technique which established a specific
profile associated with response to treatment in the biopsies
of patients with locally advanced rectal neoplasms who
underwent neoadjuvant therapy [18]. The team took biopsies
from 35 patients affected by rectal cancer T3-4/N+ prior
to the initiation of radiotherapy (45Gy) combined with
capecitabine and oxaliplatin. Following a 6-to-8-week rest
period a conventional surgical resection was performed. The
anatomical pathological response was classified according
to Mandard’s tumor regression scale: responding patients
(TRG 1) and nonresponders (TRG 2, TRG 3, TRG 4, and
TRG 5). Results were then validated through quantitative
RT-PCR. Researchers studied 373 miRNAs, 53 of which
were overexpressed in the group of responders compared
with 4 in the group of nonresponders. Of those, 14 were
selected for validation by RT-PCR and 13 of them were
confirmed. Two of the miRNAs involved in DNA repair
mechanisms stood out (miR-622 and miR-630), possibly
inhibiting the process and converging in the P53 pathway.
These two miRNAs are not expressed in samples proceeding
from responding patients and show 100% sensibility and
sensitivity.
The authors of another recently published study [19]
extracted 12 RNA samples from pretherapeutic biopsies
embedded in paraffin and then compared their RNA expres-
sion profile with response to neoadjuvant chemoradia-
tion. They identified three RNAs associated with complete
response (miR-16, miR-153, and miR-590-5p), employing
Mansard’s tumor regression grade for quantification and two
(miR-519c-3p and miR-561) that predicted good versus poor
response, with exactness close to 100%. miRNA expression
was analysed in formalin-fixed paraffin-embeddedsamples
and in fresh-frozen samples using real-time PCR. The
expression levels of miR-10b, miR-143, and miR-145 were
downregulated in both FFPE and fresh-frozen tissues, while
those for miR-21 were upregulated in tumors.







































































































































































































































































































































































































































































































































































































































BioMed Research International 7
In another retrospective study large-scalemiRNA expres-
sion analysis was performed on 20 samples of preoperative
biopsies of rectal cancer tissues [20]. All patients underwent
neoadjuvant treatment based on radiotherapy (45Gy to the
pelvis plus 5.4Gy boost to tumor) and chemotherapy with
capecitabine or 5FU followed 6 weeks later by standard
radical surgery. Response was evaluated using a grading
system adapted from Mandard and establishing an average
and a maximal percentual representation of residual cancer
cells in the cell population detected in 10 examined slices
of formalin-fixed and paraffin-embedded primary tumors.
Responders were classified as patients with tumors in TRG
1-2 and nonresponders were those with or without partial
regression (TRG 3–5). Researchers identified eight miRNAs
with different expression levels between the two groups.
Three of them (miR-215,miR190b, andmiR-29b-2)were over-
expressed, while the other five (let7e, miR-196b, miR-450a,
miR-450b-5p, and miR-99a) showed lower expression levels
in nonresponders. Using these miRNAs, 90% of responders
and 90% of nonresponders were correctly classified. Five
of them (miR-215, miR-99a∗, miR-196b, miR-450b-5p, and
let-7e) were previously correlated with radioresistance or
chemoresistance to thymidylate synthase inhibitors. There is
evidence in previous studies that MiR-215 induces inhibition
of cell proliferation and subsequent chemoresistance. The
let-7 family of miRNAs (let-7a through let-7h) regulates
expression of key oncogenes, such as RAS and MYC, and
is specifically downregulated in many cancer types. Impor-
tant proteins involved in DNA repair are among putative
targets of miR-99a∗, so upregulation of miR-99a∗ in tumors
could be associated with lower DNA repair capacity through
downregulation of these genes, which may lead to radiother-
apy sensitization. Researchers concluded that miRNAs are
part of the response mechanism involved in rectal cancer
to chemoradiotherapy and that miRNAs could represent
promising predictive biomarkers for patients undergoing
such treatment.
Hotchi’s group from Japan obtained rectal cancer samples
during colonoscopy from 43 patients, prior to preoperative
chemoradiotherapy (22 for training and 21 for testing the
outcome prediction model) [21]. Samples were used for RNA
extraction when paralleled biopsies contained at least 70%
tumor cells. Neoadjuvant treatment consisted of 4,000 cGy
of pelvic irradiation, five times a week, with a daily fraction
of 200 cGy utilizing a four-field technique concomitantly
with S1 on radiation days (a novel oral fluoropyrimidine
inhibitory for dihydropyrimidine dehydrogenase with a
potent radiosensitizing property). Surgery was performed 6–
8 weeks following completion of preoperative CRT. Response
to CRT was evaluated by three parameters:
(1) Histopathological examination of surgically resected
specimens (based on a semiquantitative classification
system). Tumors were classified as responders when
assigned to regression grade 2 or grade 3 and nonre-
sponders when assigned to grade 0 or grade 1.
(2) Response Evaluation Criteria in Solid Tumors
(RECIST): tumors were classified as responders
when assigned to complete response (CR) or
partial response (PR) and nonresponders when
stable disease (SD) or progressive disease (PD) was
reported.
(3) Downstaging (yes/no): using real-time RT-PCR in a
training set, a candidate miRNA detected by miRNA
microarray analysis was evaluated.
With regard to the histopathological examination of
surgically resected specimens, two genes are differentially
expressed at significant levels in responders and nonrespon-
ders (miR-223 and miR-142-3p), with responders showing
higher expression in comparison to nonresponders. Nine
genes were differentially expressed at significant levels with
regard to RECIST: one (miR-223) showed a higher expres-
sion, while eight showed a lower expression (miR-20b, miR-
92a, let-7a∗, miR-20a, miR-17∗, miR-106a, miR-17, and miR-
20a∗) in responders compared to nonresponders. Three
genes (miR-223, miR-630, and miR-126∗) showed a higher
expression in responders compared to nonresponders with
regard to downstaging. A candidate gene, miR-223, showed
a higher expression among responders than nonresponders
in the three parameters evaluated using real-time RT-PCR.
The miR-223 level was significantly higher in responders
compared to nonresponders. ROC curve analyses showed
that miR-223 might differentiate between responders and
nonresponders with an area under the curve (AUC) of 0.768
(95% confidence internal (CI), 0.661–0.865). At the cut-off
value of 0.4 for miR-223, the sensitivity and the specificity in
the 21 testing samples were 100 and 78.0%, respectively.
3.4. Response Prediction Using SAGE (Serial Analysis of Gene
Expression). In 2011 Casado and colleagues performed a
serial analysis of genetic expression to identify a genetic
profile that could predict response to chemoradiation therapy
in locally advanced rectal cancer [14]. An initial selection
of genes was made using SAGE analysis. They recruited 25
patients and applied a neoadjuvant therapy regimen com-
posed of oxaliplatin and raltitrexed (130mg/m2 and 3mg/m2,
days 1, 21, and 42) in three cycles, combinedwith radiotherapy
(50.4Gy in 28 fractions). Response was determined in the
surgical sample following the scale used by Dworak and
colleagues [23]. In contrast to studies presented to date, the
goal herewas to find genes predictive of a poor response.They
identified 24 genes associated with a lack of response. Based
on these results and available literature, the team selected 53
genes for a subsequent retrospective study in 94 patients with
locally advanced rectal cancer that had received neoadjuvant
treatment (under four different radiochemotherapy regi-
mens). They used stored samples of those tumors embedded
in paraffin and performed a qRT-PCR following the TaqMan
Low Density Array (TLDA) protocol. This enabled them to
identify a genetic profile composed of 13 genes that permitted
the prediction of nonresponse with an exactness of 85%,
sensibility of 87%, and specificity of 82%.This study’s weakest
point is the diversity of neoadjuvant treatments employed.
Technology based on tumor samples embedded in paraffin to
determine genetic profiles is more suitable to clinical practice
than the use ofmicroarray studies of gene expression.
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Currently, a multicentric study backed by the Grupo
Español Multidisciplinar en Cancer Digestivo (Multidisci-
plinary Spanish Group on Digestive Cancer, GEMCAD) is
underway to confirm these results.
4. Discussion
There has been a high local recurrence rate in LARC. Besides
improvements in surgical techniques, both neoadjuvant
short-course radiotherapy and long-course chemoradiation
improve oncological results [27]. After CRT, the ability to
achieve tumor reduction or even a pCR is observed in up
to 60% of the patients treated. This treatment also correlates
with a decreasing local recurrence. Conversely patients with
a poor response have a worse oncological outcome.
Modern oncological treatment decisions increasingly
depend on so-called clinical and laboratory predictive and
prognostic markers. While prognostic markers explain vari-
ability irrespective of treatment, our study intends to use
predictive markers to explain outcome variability in response
to treatment. Gene expression profile using the microarray
technology has led to a series of promising results through
tissue gene expression profiling of different malignancies,
including cancer. Interestingly, gene signatures have been
used successfully as prognostic predictor for patients with
colorectal carcinomas [9, 28].
A successful biomarker should be able to predict a
certain group of rectal cancer patients that would be likely to
experience response or even a pCR. For this group of patients,
the biomarker would be a useful prognostic factor that could
indicate a more favorable outcome, and their management
would not change from the standard treatment regimen.
Those patients with biomarkers predicting a poor response to
standard treatment could be offered adjusted therapy courses
in terms of the agents used or sequence of treatments (e.g.,
induction chemotherapy, the addition of a targeted agent
such as an EGFR antibody, or surgery without any delay,
followed by adjuvant CRT).
The literature was reviewed for studies of biomarkers
predicting response to neoadjuvant CRT for rectal cancer.
Fifteen studies evaluating genetic profiles predicting outcome
of neoadjuvant CRT in rectal cancer were analyzed. Ten of
them identified an over- or downregulated gene signature;
five studies found microRNA (miRNA) signature.
Although tissue gene microarray profiling has led to
promising data in cancer, to date, none of the identified
signatures or molecular markers in LARC has been success-
fully validated as a diagnostic or prognostic tool applicable
to routine clinical practice. Moreover, there has been little
agreement between signatures published, with scarce overlap
in the reported genes [9–13]. Only two genes, MMP4 and
FLNA, have been reported in more than one paper [10, 11, 13]
and only one of the 257 genes reported by our research group,
RRM1 (an important marker for chemotherapy resistance in
colon tumors [29]), was also identified by Nishioka et al. [13].
Significant bias was found by analyzing the literature.
The scant number of patients in the studies is one of them.
The evaluated studies examined between 12 and 94 patients.
Even if a significant correlation was determined between
a biomarker and a measurement of outcome, the literature
has failed to demonstrate reproducibility. Before the clinical
use can be established, prospective studies, including a large
number of patients should be performed in order to achieve
reproducible results.
Furthermore, significant variability in the CRT course
can hinder the interpretation of results. Neoadjuvant CRT
for LARC typically consists of 5FU and 45–50.4Gy of pelvic
irradiation. By using alternative chemotherapeutic agents
in the studies, the results are more difficult to interpret.
For example, the addition of oxaliplatin or irinotecan to
5FU for a subset of patients could confound the outcome
measurements by altering the baseline response.Variability in
the response scoring system is also a debatable bias between
the studies.
Despite this variability, our review underlines two main
hypothesis: first, the elevated expression of c-Myc mRNA as
an important marker of response to CRT in LARC as an
essential component of the neoplastic phenotype in rectal
tumors.
Second, miRNAs, highly conserved noncoding RNAs
ranging between 21 and 24 nucleotides in size, play a major
role in the posttranscriptional regulation of mRNA. The
inhibition of translation after forming a complex similar to
the RNA-interference-induced silencing complex (RISC), by
downregulating the expression of their protein-coding gene
targets, is the general mechanism of microRNA action in
animal and human cells [30, 31]. Some miRNAs function as
oncogenes, while others could function as tumor suppressors.
miRNAs are considered to be master regulators of several
important biological processes, such as cell growth, apop-
tosis, and cancer development [32–35]. miRNA expression
profiles have been shown to be promising biomarkers for
the classification or the outcome prediction of some human
cancers [35, 36]. Moreover, miRNAs are involved in different
stages of colorectal cancer pathogenesis by regulating the
expression of oncogenes and tumor suppressor genes [37].
They are also known to be involved in the regulation of
radioresistance [38, 39]. Due to their small size, miRNAs
are more stable and resistant to environmental, physical,
and chemical stresses compared to mRNAs. Therefore, their
analysis as formalin-fixed paraffin-embedded tissue samples
may provide more accurate replication of what would be
observed in fresh tissues [19]. The analysis of formalin-fixed
paraffin-embedded samples could be easily transferred to
clinical practice.
In conclusion, the current literature does not lend enough
support to any of the biomarkers to permit the clinical
application in order to predict outcome to neoadjuvant CRT
in rectal cancer.
In future clinical trials, assessing neoadjuvant CRT for
rectal cancer, these biomarkers should be prospectively eval-
uated to determine their role as predictors of outcome. It
is clear that there is a biological basis as to why some
tumors respond to CRT and that biology could be related
to the tumor, the patient, or both. In this context, the genes
identified in Mononuclear Peripheral Blood Cells could offer
new insights into the immune system’s dysregulation in
BioMed Research International 9
LARC [8] and should be further investigated. Furthermore,
the answer may not lie strictly in the genome of the tumor
but could represent epigenetic factors, and these would also
need to be explored. It is unlikely that any single factor will
determine response characteristics; therefore a multifaceted
approach will almost certainly be needed.
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